Summit Therapeutics (SUMM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock SUMM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 EarningsJuly 17 at 7:08 PM | finance.yahoo.comH.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT)July 16 at 8:56 PM | theglobeandmail.comMerakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation ShowcaseJuly 15, 2025 | tmcnet.comSummit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca DealJuly 10, 2025 | msn.comSummit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing DealJuly 9, 2025 | msn.comSummit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks RemainJuly 4, 2025 | seekingalpha.comUBS Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationJuly 2, 2025 | msn.comSummit Therapeutics Inc. Common Stock (SMMT) - NasdaqJuly 2, 2025 | nasdaq.comLineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025July 2, 2025 | finance.yahoo.comSummit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting PotentialJuly 2, 2025 | msn.comRevolution Medicines, Summit Therapeutics Partner to Evaluate Combination of Treatments in Certain CancersJune 30, 2025 | marketwatch.com2 Stocks Too Cheap to Ignore at These PricesJune 26, 2025 | msn.comSMMT Summit Therapeutics Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comH.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 TargetJune 26, 2025 | msn.comExplaining Summit's Fall Despite Positive Data In EGFR-Positive Lung CancerJune 4, 2025 | seekingalpha.comIs SMMT Stock A Buy After Its Recent Plunge?June 2, 2025 | forbes.comSummit gains as late-stage trial for lung cancer therapy hits main goalMay 30, 2025 | msn.comSummit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab ApprovalMay 30, 2025 | seekingalpha.comPfizer's Mega Deal Highlights China's Rising Role In Global PharmaMay 29, 2025 | benzinga.comSummit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025May 23, 2025 | finance.yahoo.comBioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimabMay 15, 2025 | msn.comSummit Therapeutics stock rating upgraded to Buy at TD CowenMay 9, 2025 | uk.investing.comWhy Summit Therapeutics Inc. (SMMT) Soared Last WeekMay 4, 2025 | msn.comSummit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.comEarnings call transcript: Summit Therapeutics beats Q1 2025 EPS forecastsMay 3, 2025 | uk.investing.comSummit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025May 2, 2025 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Altimmune (ALT)April 30, 2025 | theglobeandmail.comSummit Therapeutics shares tumble following interim analysisApril 26, 2025 | uk.investing.comSummit Therapeutics sinks after STAT report on ivonescimab dataApril 26, 2025 | markets.businessinsider.comSummit Therapeutics says new ivonescimab data clinically meaningfulApril 26, 2025 | markets.businessinsider.comSummit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s OptimisticApril 26, 2025 | msn.comSummit Therapeutics: New Ivonescimab Data Raise ConcernsApril 26, 2025 | seekingalpha.comSummit plunges 35%; partner Akesso wins FDA nod for cancer drugApril 25, 2025 | msn.comEvercore ISI Remains a Buy on Summit Therapeutics (SMMT)April 24, 2025 | markets.businessinsider.comSummit extends gains as cancer drug outperforms BeiGene’s TevimbraApril 24, 2025 | msn.comSummit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug TrialApril 24, 2025 | msn.comHealth Care Ticks Up Ahead of Earnings -- Health Care RoundupApril 23, 2025 | marketwatch.comTruist Financial Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)April 23, 2025 | markets.businessinsider.comSummit Therapeutics Rallies After Lung Cancer Drug Shows Positive ResultsApril 23, 2025 | marketwatch.comBullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks RemainApril 20, 2025 | seekingalpha.comSummit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial OfficerApril 14, 2025 | finance.yahoo.comHere's Why Summit Therapeutics Stock Soared 15% on FridayApril 14, 2025 | msn.comSummit Therapeutics spikes after co-CEO’s early warrants exerciseApril 10, 2025 | msn.comSummit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)March 28, 2025 | seekingalpha.comCantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight RecommendationMarch 22, 2025 | msn.comSummit rises as Cantor becomes latest to launch with a bullish viewMarch 21, 2025 | msn.comSummit Therapeutics names Robert LaCaze as Chief Commercial OfficerMarch 18, 2025 | markets.businessinsider.comEvercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform RecommendationMarch 12, 2025 | msn.comSummit Therapeutics initiated with an Outperform at Evercore ISIMarch 12, 2025 | markets.businessinsider.com2025 CAMPS Summit Selects Merakris Therapeutics’ Scientist with Inaugural “Best Comparative Trial” AwardMarch 4, 2025 | finance.yahoo.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Email Address SUMM Media Mentions By Week SUMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUMM News Sentiment▼0.390.57▲Average Medical News Sentiment SUMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUMM Articles This Week▼32▲SUMM Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AstraZeneca News Today GSK News Today Haleon News Today NIOX Group News Today Beximco Pharmaceuticals News Today Smith & Nephew News Today Integrated Diagnostics News Today ConvaTec Group News Today Hikma Pharmaceuticals News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:SUMM) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUMM Stock Alerts